Tianjin CanSino Biologics
Jing WANG , was appointed vice president for finance and capital markets on May 21, 2018, and has been the secretary of the Board since February 2017. Ms. Wang joined the Company in June 2012, and held several positions before she was appointed as vice president. Ms. Wang has led the establishment of our financing, financial management, human resources and administration systems as well as completing the fundraising of approximately RMB743 million. From July 2005 to May 2012, Ms. Wang worked at several subsidiaries of Tasly Holding Group Co., Ltd. , where she was responsible for business development of pharmaceutical products, including vaccines in domestic and overseas markets. From March 2002 to June 2005, Ms. Wang worked at Sinochem Tianjin Import and Export Corporation. Ms. Wang obtained her master’s degree in engineering from Peking University in January 2011.
This person is not in any offices
Tianjin CanSino Biologics
1 followers
Tianjin CanSino Biotech Inc. is an emerging biotechnology company dedicated to vaccine research, development and commercialization. We seek to address the pressing unmet medical needs by developing and marketing leading-edge, high quality vaccines for China and other emerging markets at affordable prices.